Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05867160

Adjunctive Anti-seizure Medication (ASM) Real World Evidence (RWE) Study

The purpose of this study is to describe the effectiveness of the adjunctive ASM treatment on the clinical response, safety profile and quality of life of patients affected by focal onset seizures in a real-world setting.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Epilepsy Brain Diseases Central Nervous System Diseases Nervous System Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Seizures Signs and Symptoms

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Fondazione IRCCS Istituto Neurologico "Carlo Besta" U.O. Epilettologia Clinica e Sperimentale - Centro di Medicina del Sonno

Milan, 20133, Italy

About this study

The aim of the study is to assess the effectiveness and safety of adjunctive therapy in a real-world setting of patients affected by focal-onset seizures who are eligible to start the treatment with ASM as adjunctive therapy according to the physician's judgment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patients of any ethnic origin ≥18 years old at baseline.
  • Patients with diagnosis of focal-onset seizures with or without secondary generalization.
  • Patients should have been eligible to start treatment with ASM as adjunctive therapy according to the physician's judgement prior to the inclusion.
  • Patients should have clinical history of treatment failure with at least 2 ASMs.
  • Patients using their seizure diary as part of their standard of care for at least 3 months prior to -the study entry (diary can be paper or electronic, filled in by patient and/or family members).
  • Written informed consent (including data privacy consent) signed by the patient, legal guardian, or legally authorized representative prior to entering the study in accordance with the ICH GCP guidelines

Exclusion criteria

  • Patients who meet any of the contraindications to the administration of adjunctive ASMs according to their approved SmPC.
  • Progressive neurological disease, including degenerative CNS diseases and progressive tumors.
  • Patients with unstable psychiatric diagnosis that may confound participants' ability to participate in the study or that may prevent completion of the protocol-specified assessments (e.g., in the judgement of the Investigator, pose an appreciable risk for suicide, including suicidal behavior and ideation within 6 months prior to enrollment, current psychotic disorder, acute mania).
  • Evidence of clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal disease) that in the opinion of the Investigator could affect the participant's safety or interfere with study assessments.
  • Patients with substance abuse or dependence (except for caffeine and nicotine).
  • Patients participating in any pharmacological or nonpharmacological interventional study within 30 days prior to baseline.

Treatment and study plan

ASM as adjunctive therapy

Other

ASM approved as adjunctive therapy

Primary outcomes

  1. Change in seizure frequency at 6 months of maintenance

    Time frame: At 6 months of maintenance compared to baseline

    The effectiveness of adjunctive ASM is measured as change in seizure frequency at 6 months of maintenance compared to baseline

Secondary outcomes

  1. Change in seizure frequency at 3, 9, 12 months of maintenance

    Time frame: At 3, 9, 12 months of maintenance compared to baseline

    The effectiveness of adjunctive ASM is measured as change in seizure frequency at 3, 9, 12 months of maintenance compared to baseline

  2. 50, 75, 90 Percent Responder rate

    Time frame: At 3, 6, 9, and 12 months of maintenance phase.

    The effectiveness is measured as 50, 75, 90 Percent Responder rate

  3. 100 Percent Responder rate

    Time frame: At 3, 6, 9, and 12 months of maintenance phase.

    The effectiveness is measured as number/percentage of seizure free patients

  4. Retention rate

    Time frame: At 3, 6, 9, and 12 months of maintenance phase.

    The effectiveness is measured as percentage of patients remaining in the study and on adjunctive therapy

  5. Anxiety assessment

    Time frame: At baseline, immediately after completion of titration, at 3 months, 6 months, and 12 months of maintenance phase.

    The assessment is measured by means of the Generalized Anxiety Disorder (GAD-7) scale. Scoring GAD-7 Anxiety Severity is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." GAD-7 total score for the seven items ranges from 0 to 21. 0-4: minimal anxiety 5-9: mild anxiety 10-14: moderate anxiety 15-21: severe anxiety.

  6. Depression assessment

    Time frame: At baseline, immediately after completion of titration, at 3 months, 6 months, and 12 months of maintenance phase.

    The assessment is measured through the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) scale. This is a validated screening tool for depression in patients with epilepsy that consists of a 6- item questionnaire. NDDI-E scores greater than 15 were considered positive for depression, as this score was previously shown to have a specificity of 90%, sensitivity of 81%, and positive predictive value of 0.62 for a diagnosis of major depression.

  7. Quality of life (QOL)

    Time frame: At baseline, immediately after completion of titration, at 3 months, 6 months, and 12 months of maintenance phase.

    The quality of life is measured by means the Quality Of Life In Epilepsy (QOLIE-31-P) questionnaire. This is a 38 questions survey of health-related quality of life for adults (18 years or older) with epilepsy. This version differs from the original QOLIE-31 (version 1) in the addition of questions about how much distress you feel about problems and worries related to epilepsy. This questionnaire should be completed only by the person who has epilepsy (not a relative or friend). Patients are asked to answer every question by circling the appropriate number (1, 2, 3...).

  8. Cognitive assessment

    Time frame: At baseline, immediately after completion of titration, at 3 months, 6 months, and 12 months of maintenance phase.

    The assessment of perceived cognitive deficits is measured through the Perceived Deficits Questionnaire (PDQ-5). The PDQ-5 assesses cognitive dysfunction in people with depression. This patient-reported questionnaire includes five items measuring attention/concentration, retrospective memory, prospective memory, and planning/organization over the past four weeks. The total score ranges from 0 to 20; higher scores indicate greater perceived cognitive dysfunction.

  9. Adverse events (AEs)

    Time frame: Through study completion, an average of 1 year

    Number of Adverse events (AEs) occurred (including AEs of special interest as Drug Reaction with Eosinophilia and Systemic Symptoms, rash/hypersensitivity, etc.).

Sponsors and collaborators

Lead sponsor

Aziende Chimiche Riunite Angelini Francesco S.p.A

Industry

Collaborators

  • Hippocrates Research

Registry information

Official study title

A 12-month, Prospective, Observational Study in Adult Patients With Focal Onset Seizures Who Are Treated With Adjunctive ASM in Real World Setting

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
May 19, 2023
Registry last updated
Sep 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.